More specifically, subtle complexin 1 (CPLX1) down-regulations were shown to distinguish prodromal PD cohorts (presymptomatic PARK4 heterozygotes and RBD individuals) from controls, suggesting that CPLX1 loss of function may act as a biomarker and modifier gene of PD risk [22]. Here, SNCA is linked to Parkinson disease.